| controls | HCC | |||
---|---|---|---|---|---|
HC (n = 10) | CHB (n = 15) | LC (n = 15) | 0 + A (n = 25) | B + C (n = 33) | |
Gender (Male/Female) | 7/3 | 9/6 | 11/4 | 19/6 | 30/3 |
Age | 51.39 ± 1.49 | 49.56 ± 12 | 48.33 ± 9.11 | 52.53 ± 5.80 | 51.82 ± 11.82 |
HBV/HCV/other | / | / | / | 21/3/1 | 29/3/1 |
HBV-DNA (positive/negative/ND) | / | 8/7/0 | 5/10/0 | 4/6/15b | 9/10/14b |
Tumour number (solitary/multiple) | / | / | / | 21/4 | 13/20 |
Tumour volume (S/H) c | / | / | / | 19/6 | 10/23 |
VI/M (no/yes) | / | / | / | 25/0 | 18/15 |
Differentiation (well/moderate/poor/ND) | / | / | / | 2/2/3/18 | 1/6/4/22 |
Curative therapy (no/yes) | / | / | / | 3/22 | 17/16 |
Recurrence at 1-year (no/yes) | / | / | / | 11/11 | 5/11 |
WBC (109/L) | 5.22 ± 1.26 | 6.18 ± 2.29 | 4.83 ± 1.88 | 4.34 ± 1.63b | 5.26 ± 2.39 |
HGB (g/L) | 141.29 ± 11.48 | 147.17 ± 21.97 | 154.33 ± 18.49 | 141.42 ± 19.39 | 141.16 ± 19.67 |
PLT (109/L) | 221.43 ± 72.04 | 199.17 ± 70.41 | 128.42 ± 73.48a, b | 103.88 ± 48.64a, b | 154.66 ± 90.71 |
ALT (U/L) | N.D. | 35.13 ± 26.50 | 42.29 ± 43.37 | 32.17 ± 23.26 | 48.88 ± 38.08 |
AST (U/L) | N.D. | 41.07 ± 47.89 | 43 ± 31.51 | 36.30 ± 17.38 | 42.92 ± 23.08b |
TBiL (μmmol/L) | N.D. | 16.49 ± 6.08 | 33.16 ± 23b | 21.02 ± 12.41 | 17.90 ± 9.15 |
ALB (g/L) | N.D. | 44.78 ± 3.31 | 42.34 ± 5.94 | 38.32 ± 5.58b | 39.82 ± 4.91b |
PT (s) | N.D. | N.D. | 15.27 ± 4.65 | 13.10 ± 1.61 | 12.37 ± 1.26 |
PTA (%) | N.D. | N.D. | 70.33 ± 17.88 | 80.17 ± 13.54 | 86.97 ± 11.53 |
AFP (ng/mL) | / | / | / | 169.21 ± 298.08 | 8729.39 ± 31,115.08 |
PIVKA-II (mAU/mL) | / | / | / | 355.73 ± 603.26 | 3574.86 ± 7725.33 |